Results 171 to 180 of about 3,459,561 (335)

The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Hypertension and diabetes frequently coexist, yet the net clinical impact of intentionally combining antihypertensive (AHTN) and antidiabetic (ADA) therapies on cardiovascular (CV) outcomes is uncertain. Here we quantified the effects of AHTN and ADA co‐therapy on CV and blood pressure (BP)/heart rate (HR) outcomes.
Wan Chin Hsieh, Brandon Michael Henry, István Édes   +2 more
wiley   +1 more source

Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

European Heart Journal - Cardiovascular Pharmacotherapy, 2018
G. Rosano, J. Tamargo, K. Kjeldsen, M. Lainščak, S. Agewall, S. Anker, C. Ceconi, A. Coats, H. Drexel, G. Filippatos, J. Kaski, L. Lund, A. Niessner, P. Ponikowski, G. Savarese, T. Schmidt, P. Seferovic, S. Wassmann, T. Walther, B. Lewis   +19 more
semanticscholar   +1 more source

Cost‐Effectiveness of NT‐proBNP–Guided Cardiovascular Screening in Chinese Adults With Type 2 Diabetes: Real‐World Evidence From the Hong Kong Diabetes Biobank

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Heart failure (HF) is among the most costly and prevalent complications of type 2 diabetes (T2D), with annual incremental healthcare costs reaching US$12800 in Hong Kong. We evaluated the cost‐effectiveness of NT‐proBNP‐guided cardiovascular risk stratification to guide cardioprotective treatment. Materials and Methods We developed a four‐
Abby Q. Y. Li, Benjamin Yarnoff, Claudia H. T. Tam, Juliana C. N. Chan, Ronald C. W. Ma, Juliana N. M. Lui, Hong Kong Diabetes Biobank Study Group   +6 more
wiley   +1 more source

Novel inhibitors of the cellular renin‐angiotensin system components, poricoic acids, target Smad3 phosphorylation and Wnt/β‐catenin pathway against renal fibrosis

British Journal of Pharmacology, 2018
Ming Wang, Dan-Qian Chen, Lin Chen, Gang Cao, Hui Zhao, Dan Liu, N. Vaziri, Yan Guo, Ying-yong Zhao   +8 more
semanticscholar   +1 more source

Combining Sodium–Glucose Co‐Transporter‐2 Inhibitor Plus Glucagon‐Like Peptide‐1 Receptor Agonist for Glucose‐Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real‐World Clinical Practice (CombiKid Study)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium–glucose co‐transporter 2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have separately shown renoprotective effects in clinical trials in people with type 2 diabetes. It is unclear whether combining these agents produces incremental kidney outcome benefits. Materials and Methods Retrospective cohort
William Hinton, Mark Joy, Anna K. Forbes, Martin B. Whyte, José M. Ordóñez‐Mena, Xuejuan Fan, Filipa Ferreira, Bernardo Meza‐Torres, Neil Munro, Simon de Lusignan, David C. Wheeler, Michael D. Feher   +11 more
wiley   +1 more source

Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Empagliflozin is renoprotective in Type 2 diabetes mellitus (T2DM). Our primary aim was to assess empagliflozin's effect on glomerular filtration rate and renal vascular resistance using multiparametric MRI (MpMRI). Our secondary aim was to assess the impact of empagliflozin on additional MpMRI‐derived metrics including markers of tissue ...
Ruth P. Lim, Salma Qassin, Lucy McKenna, Emma Hornsey, Dominic Italiano, Leonid Churilov, Richard J. MacIsaac, Jas‐mine Seah, Elif I. Ekinci, The Austin EMPA‐MRI Study Group   +9 more
wiley   +1 more source

Potassium and the use of renin–angiotensin–aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT‐CHF

European Journal of Heart Failure, 2018
Joost C. Beusekamp, J. Tromp, H. H. van der Wal, S. Anker, J. Cleland, K. Dickstein, G. Filippatos, P. van der Harst, H. Hillege, C. Lang, M. Metra, L. Ng, P. Ponikowski, N. Samani, D. V. van Veldhuisen, A. Zwinderman, P. Rossignol, F. Zannad, A. Voors, P. van der Meer   +19 more
semanticscholar   +1 more source

Mitral regurgitation and decompensated heart failure in a young pregnant pony mare: An aetiological challenge

Equine Veterinary Education, EarlyView.
Summary A 4‐year‐old, 6‐month pregnant, Welsh pony mare presented with severe acute clinical signs including depression, anorexia, pale mucous membranes, tachycardia with a grade 4/6 holosystolic murmur and moderate expiratory dyspnoea with diffuse wheezes. There was no evidence of placentitis or fetal distress.
M. F. David, L. Cannon, A. Tortereau, A. Thomas‐Cancian, I. Desjardins   +4 more
wiley   +1 more source

Cellular control of renin secretion

, 1989
Kurtz, Armin
core   +1 more source

Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study

Hepatology Research, EarlyView.
Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori, Kazuhiro Yamamoto, Hiroshi Aoi, Yusuke Koizumi, Makoto Kuromatsu, Aiko Fukui, Hiroyo Okamoto, Atsushi Hirata, Kentaro Shinmori, Yuki Imanaka, Miyu Namba, Keisuke Nakanishi, Syunsuke Kitamura, Hideo Tsushima, Ikuko Yano, Kei Moriya, Masaru Matsui, Shigeki Ikushima   +17 more
wiley   +1 more source